Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Safety and Efficacy Study to Compare Dapsone Dermal Gel With Vehicle Control in Patients With Acne Vulgaris

Trial Profile

A Safety and Efficacy Study to Compare Dapsone Dermal Gel With Vehicle Control in Patients With Acne Vulgaris

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapsone (Primary)
  • Indications Acne vulgaris
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 08 Mar 2016 Pooled results (n=4340) assessing the effects of age, gender and race of this and other trial (see profile: 238538) presented at the 74th Annual Meeting of the American Academy of Dermatology
    • 08 Mar 2016 Pooled results (n=4340) assessing the efficacy and safety of this and other trial (see profile: 238538) presented at the 74th Annual Meeting of the American Academy of Dermatology
    • 08 Mar 2016 Primary endpoint (Change from Baseline in Noninflammatory Facial Lesion Counts) has been met, as per the results presented at the 74th Annual Meeting of the American Academy of Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top